8-K: Integer Holdings Reports Strong Q1 2025 Results, Raises Adjusted EPS Outlook

Integer Holdings Corporation announced a 7% increase in sales and a 14% increase in adjusted operating income for Q1 2025, leading to an increased adjusted EPS outlook for the year.

Summary

• Integer Holdings Corporation reported its first quarter 2025 results, showing a strong start to the year.
• Sales increased by 7% to $437 million, with organic growth of 6%.
• GAAP operating income rose by $11 million to $50 million, a 28% increase.
• Non-GAAP adjusted operating income increased by $9 million to $71 million, a 14% increase.
• GAAP income from continuing operations decreased by $43 million to a $22 million loss, primarily due to debt conversion inducement expense.
• Non-GAAP adjusted net income increased by $7 million to $46 million, a 19% increase.
• GAAP diluted EPS from continuing operations decreased by $1.25 to a loss of $0.66.
• Non-GAAP adjusted EPS increased by $0.17 to $1.31.
• Adjusted EBITDA increased by $11 million to $92 million, a 14% increase.
• The company closed its offering of $1.0 billion aggregate principal amount of 1.875% convertible notes due 2030 on March 18, 2025, expecting a $13 million reduction to interest expense in 2025.
• Total debt increased by $245 million to $1.235 billion from the end of 2024, primarily to finance acquisitions and costs associated with the convertible note offering.
• The leverage ratio as of March 28, 2025, was 3.3 times adjusted EBITDA.
• The company is reiterating its 2025 sales outlook of 8% to 10% growth and raising its adjusted net income growth outlook to 19% to 26%.

Sentiment

Score: 7

Explanation: The document presents a generally positive outlook with strong sales growth and increased adjusted EPS guidance, although there are some concerns regarding increased debt and a GAAP loss due to debt conversion expenses.

Positives

• Sales increased by 7% to $437 million, with organic growth of 6%.
• Non-GAAP adjusted operating income increased by 14% to $71 million.
• Adjusted EBITDA increased by 14% to $92 million.
• The company expects a $13 million reduction in interest expense in 2025 due to the convertible notes offering.
• The company is raising its adjusted net income growth outlook to 19% to 26% for 2025.
• Cardio & Vascular sales increased 17% due to new product ramps and acquisitions.
• Cardiac Rhythm Management & Neuromodulation sales increased 2% due to strong growth in emerging neuromodulation customers.

Negatives

• GAAP income from continuing operations decreased by $43 million to a $22 million loss, primarily due to debt conversion inducement expense.
• GAAP diluted EPS from continuing operations decreased by $1.25 to a loss of $0.66.
• Other Markets sales decreased 37% primarily driven by the planned multi-year Portable Medical exit.

Risks

• The company's total debt increased by $245 million to $1.235 billion.
• The leverage ratio as of March 28, 2025, was 3.3 times adjusted EBITDA.
• The company's future performance is subject to various risks and uncertainties described in its SEC filings, including operational, strategic, financial, indebtedness, legal, and compliance risks.

Future Outlook

Integer expects sales growth of 8% to 10% and is raising its adjusted net income growth outlook to 19% to 26% for 2025.

Management Comments

• Integer started the year off strong with first quarter 2025 sales growing at 7% year-over-year as we continue to execute our strategy by launching new products and adding capabilities in targeted growth markets.
• Integer also delivered 14% adjusted operating income growth, said Joseph Dziedzic, Integers president and CEO.
• We continue to expect sales growth of 8% to 10% and are raising our adjusted net income growth outlook to 19% to 26%.

Industry Context

Integer Holdings operates in the medical device contract development and manufacturing organization (CDMO) industry, serving the cardiac rhythm management, neuromodulation, and cardio and vascular markets. The company's performance is influenced by factors such as competition, technological changes, and healthcare industry cost containment measures.

Comparison to Industry Standards

• Integer's growth in the Cardio & Vascular segment, with a 17% increase, is strong compared to competitors in the medical device industry.
• The company's adjusted EBITDA margin of approximately 21% (based on $92 million adjusted EBITDA on $437 million sales) is competitive within the CDMO sector.
• Comparable companies in the medical device CDMO space include names like Medtronic, Stryker, and Boston Scientific, though Integer focuses specifically on contract manufacturing.
• Integer's leverage ratio of 3.3x adjusted EBITDA is within a reasonable range for companies in this sector, but it is important to monitor given the increased debt from acquisitions and the convertible note offering.

Management Changes

Stakeholder Impact

• Shareholders can expect potential dilution from the convertible notes, but also benefit from the increased adjusted EPS outlook.
• Employees may experience changes due to restructuring and integration activities.
• Customers can expect continued innovation and high-quality products and solutions.
• Suppliers may see increased demand due to the company's growth.
• Creditors should monitor the company's debt levels and leverage ratio.

Next Steps

• The company will host a conference call on April 24, 2025, to discuss the results.
• The company will continue to execute its strategy by launching new products and adding capabilities in targeted growth markets.
• The company will monitor its debt levels and leverage ratio.

Key Dates

Keywords

Integer Holdings, financial results, Q1 2025, medical devices, sales growth, adjusted EPS, convertible notes, acquisitions, EBITDA, debt